Business Services Industry

Ostex shareholders elect Glaser

Business Wire, Sept 28, 1995

SEATTLE--(BUSINESS WIRE)--Sept. 28, 1995--Ostex International Inc. (NASDAQ:OSTX) said today that shareholders at the company's annual meeting elected Robert J. Glaser as a director for a three-year term.

Shareholders also ratified the appointment of Arthur Andersen LLP as auditors for the fiscal year ended Dec. 31, 1995.

Glaser was appointed to Ostex's board of directors in May, filling a vacancy resulting from the resignation of Errol S. McKinney. Glaser is senior vice president, marketing, U.S. Human Health, with Merck & Co. (NYSE:MRK) in West Point, Penn.

He is principally responsible for the commercialization of Merck's new drug Fosamax, a therapy for osteoporosis currently under review by the Food and Drug Administration.

Ostex International is a Seattle-based company engaged in the discovery and development of diagnostics and therapeutics for diseases of the skeleton. The company completed its initial public offering of common stock on Jan. 25, 1995.

CONTACT: Ostex International Inc., Seattle

John Brenneman, 206/689-0605

COPYRIGHT 1995 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

White Papers, Webcasts, and Resources

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale